582 results on '"Egeo A"'
Search Results
2. Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
- Author
-
Barbanti, Piero, Egeo, Gabriella, Proietti, Stefania, d’Onofrio, Florindo, Aurilia, Cinzia, Finocchi, Cinzia, Di Clemente, Laura, Zucco, Maurizio, Doretti, Alberto, Messina, Stefano, Autunno, Massimo, Ranieri, Angelo, Carnevale, Antonio, Colombo, Bruno, Filippi, Massimo, Tasillo, Miriam, Rinalduzzi, Steno, Querzani, Pietro, Sette, Giuliano, Forino, Lorenzo, Zoroddu, Francesco, Robotti, Micaela, Valenza, Alessandro, Camarda, Cecilia, Borrello, Laura, Aguggia, Marco, Viticchi, Giovanna, Tomino, Carlo, Fiorentini, Giulia, Orlando, Bianca, Bonassi, Stefano, and Torelli, Paola
- Published
- 2024
- Full Text
- View/download PDF
3. Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
- Author
-
Piero Barbanti, Gabriella Egeo, Stefania Proietti, Florindo d’Onofrio, Cinzia Aurilia, Cinzia Finocchi, Laura Di Clemente, Maurizio Zucco, Alberto Doretti, Stefano Messina, Massimo Autunno, Angelo Ranieri, Antonio Carnevale, Bruno Colombo, Massimo Filippi, Miriam Tasillo, Steno Rinalduzzi, Pietro Querzani, Giuliano Sette, Lorenzo Forino, Francesco Zoroddu, Micaela Robotti, Alessandro Valenza, Cecilia Camarda, Laura Borrello, Marco Aguggia, Giovanna Viticchi, Carlo Tomino, Giulia Fiorentini, Bianca Orlando, Stefano Bonassi, Paola Torelli, and for the Italian Migraine Registry study group
- Subjects
Fremanezumab ,Migraine treatment ,CGRP monoclonal antibody ,Real-world ,Long-term treatment ,Psychiatric comorbidities ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Abstract Introduction Long-term (1-year) fremanezumab treatment proved to be effective, safe, and well tolerated in individuals with migraine and 3 treatment failures and various comorbidities. Methods A 48-week, prospective, multicenter (n = 26), cohort study assessed fremanezumab’s effectiveness, safety, and tolerability in consecutive adults with HFEM or CM with > 3 treatment failures. Primary endpoint was variation from baseline in monthly migraine days (MMD) in HFEM and monthly headache days (MHD) in CM at weeks 45–48. Secondary endpoints were changes in monthly analgesic medications, Numerical Rating Scale (NRS), Headache Impact Test (HIT-6), and the Migraine Disability Assessment Scale (MIDAS) scores and ≥ 50%, ≥ 75%, and 100% responder rates. Results Of 533 participants who had received ≥ 1 fremanezumab dose, 130 were treated for ≥ 48 weeks and considered for effectiveness analysis. No participant missed any treatment dosage every other consecutive month during the 12-month period. Primary endpoint: fremanezumab significantly (p 3) therapeutic failures, even in the presence of concomitant medication overuse, psychiatric comorbidities, or both. The effectiveness-to-tolerability ratio appears to be better in RWE than in RCTs.
- Published
- 2024
- Full Text
- View/download PDF
4. Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
- Author
-
Piero Barbanti, Gabriella Egeo, Stefania Proietti, Florindo d’Onofrio, Cinzia Aurilia, Cinzia Finocchi, Laura Di Clemente, Maurizio Zucco, Alberto Doretti, Stefano Messina, Massimo Autunno, Angelo Ranieri, Antonio Carnevale, Bruno Colombo, Massimo Filippi, Miriam Tasillo, Steno Rinalduzzi, Pietro Querzani, Giuliano Sette, Lorenzo Forino, Francesco Zoroddu, Micaela Robotti, Alessandro Valenza, Cecilia Camarda, Laura Borrello, Marco Aguggia, Giovanna Viticchi, Carlo Tomino, Giulia Fiorentini, Bianca Orlando, Stefano Bonassi, Paola Torelli, and for the Italian Migraine Registry study group
- Subjects
Neurology. Diseases of the nervous system ,RC346-429 - Published
- 2024
- Full Text
- View/download PDF
5. Very-low-calorie ketogenic diet vs hypocaloric balanced diet in the prevention of high-frequency episodic migraine: the EMIKETO randomized, controlled trial
- Author
-
Massimiliano Caprio, Eleonora Moriconi, Elisabetta Camajani, Alessandra Feraco, Vincenzo Marzolla, Laura Vitiello, Stefania Proietti, Andrea Armani, Stefania Gorini, Caterina Mammi, Gabriella Egeo, Cinzia Aurilia, Giulia Fiorentini, Carlo Tomino, and Piero Barbanti
- Subjects
VLCKD ,Migraine treatment ,Prevention ,Diet ,Weight loss ,Ketone bodies ,Medicine - Abstract
Abstract Background Migraine is the second world’s cause of disability. Among non-pharmacological treatments, nutritional intervention, particularly ketogenic diet, represents one of the most promising approaches. Methods This a prospective, single center, randomized, controlled study aimed at evaluating the efficacy of a very low-calorie ketogenic diet (VLCKD) compared to a hypocaloric balanced diet (HBD) in migraine prophylaxis in patients affected by high-frequency episodic migraine (HFEM) with a Body Mass Index (BMI) > 27 kg/m2. Fifty-seven patients were randomly assigned to a VLCKD (group 1) or HBD (group 2). Group 1 patients followed a VLCKD for 8 weeks, followed by a low calorie diet (LCD, weeks 9–12), and a HBD (weeks 13–24), whereas group 2 patients followed a HBD from week 0 to 24. Anthropometric indexes, urine and blood chemistry were assessed at enrollment, baseline, weeks 4, 8, 12, and 24. Migraine characteristics were evaluated at baseline, weeks 8, 12 and 24. Change in monthly migraine days (MMDs) at weeks 5–8 compared to baseline was the primary endpoint. Secondary endpoints encompassed changes in visual analogue scale (VAS), Headache Impact Test-6 (HIT-6) and Short Form Health Survey-36 (SF-36) scores. We also studied effects on circulating lymphocytes and markers of inflammation, changes in plasma aldosterone and renin levels before and after VLCKD or HBD treatment. Results Reduction from baseline in MMDs was greater in VLCKD compared to HBD group at week 8 (p = 0.008), at week 12 (p = 0.007), when ketosis had been interrupted by carbohydrates reintroduction, and at week 24 (p = 0.042), when all patients were following the same dietary regimen. Quality of life scores (SF-36) were improved in VLCKD group at week 8 and 12, and were also improved in HBD group, but only at week 12. Weight-loss was significantly higher in VLCKD group at week 8 (p = 0.002) and week 12 (p = 0.020). At the end of the study weight loss was maintained in VLCKD group whereas a slight weight regain was observed in HBD group. Inflammatory indexes, namely C reactive protein (CRP), neutrophil to lymphocyte ratio (NLR) and total white blood cell count (WBC) were significantly reduced (p
- Published
- 2023
- Full Text
- View/download PDF
6. Very-low-calorie ketogenic diet vs hypocaloric balanced diet in the prevention of high-frequency episodic migraine: the EMIKETO randomized, controlled trial
- Author
-
Caprio, Massimiliano, Moriconi, Eleonora, Camajani, Elisabetta, Feraco, Alessandra, Marzolla, Vincenzo, Vitiello, Laura, Proietti, Stefania, Armani, Andrea, Gorini, Stefania, Mammi, Caterina, Egeo, Gabriella, Aurilia, Cinzia, Fiorentini, Giulia, Tomino, Carlo, and Barbanti, Piero
- Published
- 2023
- Full Text
- View/download PDF
7. Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study
- Author
-
Barbanti, Piero, Egeo, Gabriella, Aurilia, Cinzia, Torelli, Paola, Finocchi, Cinzia, d’Onofrio, Florindo, d’Onofrio, Luigi, Rao, Renata, Messina, Stefano, Di Clemente, Laura, Ranieri, Angelo, Autunno, Massimo, Sette, Giuliano, Colombo, Bruno, Carnevale, Antonio, Aguggia, Marco, Tasillo, Miriam, Zoroddu, Francesco, Frediani, Fabio, Filippi, Massimo, Tomino, Carlo, Proietti, Stefania, and Bonassi, Stefano
- Published
- 2023
- Full Text
- View/download PDF
8. Evaluating the Effectiveness, Tolerability, and Safety of Eptinezumab in High-Frequency and Chronic Migraine in Real World: EMBRACE—The First Italian Multicenter, Prospective, Real-Life Study
- Author
-
Piero Barbanti, Bianca Orlando, Gabriella Egeo, Florindo d’Onofrio, Alberto Doretti, Stefano Messina, Massimo Autunno, Roberta Messina, Massimo Filippi, Giulia Fiorentini, Cristina Rotondi, Stefano Bonassi, and Cinzia Aurilia
- Subjects
migraine ,eptinezumab ,anti-CGRP mAbs ,treatment ,real-life ,disability ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
We conducted a multicenter, prospective study (EMBRACE) evaluating the real-life effectiveness, safety, and tolerability of eptinezumab (100 mg/300 mg)—a monoclonal antibody targeting the calcitonin-gene-related peptide (anti-CGRP mAb)—in high-frequency episodic migraine (HFEM) or chronic migraine (CM). The primary endpoint was the change in monthly migraine days (MMD) for HFEM or monthly headache days (MHD) for CM at weeks 9–12 compared to baseline. The secondary endpoints included changes in monthly analgesic intake (MAI), Numerical Rating Scale (NRS), Headache Impact Test (HIT-6), Migraine Disability Assessment Scale (MIDAS), Migraine Interictal Burden Scale (MIBS-4), and responder rates. The safety analysis involved 44 subjects; the effectiveness analysis included 26 individuals. Eptinezumab was well-tolerated. In CM patients, eptinezumab significantly reduced MHD (−16.1 ± 9.9, p < 0.001), MAI, NRS, HIT-6, MIDAS, and MIBS-4. In HFEM patients, it significantly reduced NRS, HIT-6, MIDAS, and MIBS-4, though reductions in MMD (−3.3 ± 4.5) and MAI were not statistically significant. Overall, ≥50% and ≥75% response rates were 61.5% and 30.8%, respectively (60% and 30% in non-responders to subcutaneous anti-CGRP mAbs). The clinical change was rated as much or very much improved by 61.0% of the patients. Eptinezumab demonstrated high effectiveness, safety, and tolerability in real-life among hard-to-treat migraine patients with multiple treatment failures, including anti-CGRP mAbs.
- Published
- 2024
- Full Text
- View/download PDF
9. Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study
- Author
-
Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Paola Torelli, Cinzia Finocchi, Florindo d’Onofrio, Luigi d’Onofrio, Renata Rao, Stefano Messina, Laura Di Clemente, Angelo Ranieri, Massimo Autunno, Giuliano Sette, Bruno Colombo, Antonio Carnevale, Marco Aguggia, Miriam Tasillo, Francesco Zoroddu, Fabio Frediani, Massimo Filippi, Carlo Tomino, Stefania Proietti, Stefano Bonassi, and for the FRIEND-Study Group
- Subjects
Fremanezumab ,Migraine treatment ,CGRP monoclonal antibody ,Real-world ,Long-term treatment ,Medicine - Abstract
Abstract Background To verify the long-term (24-week) efficacy, safety, and tolerability of fremanezumab in real-life patients with high-frequency episodic migraine (HFEM: ≥ 8 days/month) or chronic migraine (CM: ≥ 15 days/month), and multiple preventive treatment failures. Methods This is a prospective, cohort, real-life study at 28 headache centers on consecutive patients affected by HFEM or CM with multiple preventive treatment failures who were prescribed subcutaneous fremanezumab (225 mg monthly/675 mg quarterly) for ≥ 24 weeks. Primary endpoint was the change in monthly migraine days (MMDs) in HFEM and monthly headache days (MHDs) in CM at weeks 21–24 compared to baseline. Secondary endpoints encompassed changes in monthly analgesic medications, ≥ 50%, ≥ 75%, and 100% responder rates, and variation in NRS, HIT-6 and MIDAS scores at the same time interval. Changes in MMDs/MHDs, monthly analgesic medications, ≥ 50%, ≥ 75%, and 100% responder rates, and variation in NRS and HIT-6 scores at week 4 were also monitored. Results Four hundred ten patients who had received ≥ 1 dose of fremanezumab were considered for safety analysis while 148 patients treated for ≥ 24 weeks were included in the efficacy analysis. At weeks 21–24, fremanezumab significantly (p
- Published
- 2023
- Full Text
- View/download PDF
10. Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients
- Author
-
Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Claudia Altamura, Florindo d’Onofrio, Cinzia Finocchi, Maria Albanese, Marco Aguggia, Renata Rao, Maurizio Zucco, Fabio Frediani, Massimo Filippi, Roberta Messina, Sabina Cevoli, Antonio Carnevale, Giulia Fiorentini, Stefano Messina, Francesco Bono, Paola Torelli, Stefania Proietti, Stefano Bonassi, Fabrizio Vernieri, and for the Italian Migraine Registry study group
- Subjects
Migraine ,Predictors ,AntiCGRP mAbs ,Unilateral cranial autonomic symptoms ,Allodynia ,Registry ,Medicine - Abstract
Abstract Background and objectives The identification of predictors of response to antiCGRP mAbs could favor tailored therapies and personalized treatment plans. This study is aimed at investigating predictors of ≥ 50%, ≥ 75% and 100% response at 24 weeks in patients with high-frequency episodic (HFEM: 8–14 days/month) or chronic migraine (CM). Methods This is a large, multicenter, cohort, real-life study. We considered all consecutive adult patients affected by HFEM or CM who were prescribed antiCGRP mAbs for ≥ 24 weeks in 20 headache centers. Patients were interviewed face-to-face using a shared semi-structured questionnaire carefully exploring socio-demographic and clinical characteristics. Patients received subcutaneous erenumab (70 mg or140 mg, monthly), galcanezumab (120 mg monthly, following a 240 mg loading dose), or fremanezumab (225 mg, monthly or 675 mg, quarterly) according to drug market availability, physician’s choice, or patient’s preference. The primary endpoint of the study was the assessment of ≥ 50% response predictors at 24 weeks. Secondary endpoints included ≥ 75% and 100% response predictors at 24 weeks. Results Eight hundred sixty-four migraine patients had been treated with antiCGRP mAbs for ≥ 24 weeks (erenumab: 639 pts; galcanezumab: 173 pts; fremanezumab: 55 pts). The ≥50% response (primary endpoint) in HFEM was positively associated with unilateral pain (UP) + unilateral cranial autonomic symptoms (UAs) (OR:4.23, 95%CI:1.57–11.4; p = 0.004), while in CM was positively associated with UAs (OR:1.49, 95%CI:1.05–2.11; p = 0.026), UP + UAs (OR:1.90, 95%CI:1.15–3.16; p = 0.012), UP + allodynia (OR:1.71, 95%CI:1.04–2.83; p = 0.034), and negatively associated with obesity (OR:0.21, 95%CI:0.07–0.64; p = 0.006). The 75% response (secondary endpoint) was positively associated with UP + UAs in HFEM (OR:3.44, 95%CI:1.42–8.31; p = 0.006) and with UP + UAs (OR:1.78, 95%CI:1.14–2.80; p = 0.012) and UP + allodynia (OR:1.92, 95%CI:1.22–3.06; p = 0.005) in CM. No predictor of 100% response emerged in patients with HFEM or CM. Conclusions A critical evaluation of headache characteristics indicating peripheral or central sensitization may help in predicting responsiveness to antiCGRP mAbs in HFEM and CM. A more precise pain profiling may represent a steppingstone for a mechanism-based approach and personalized treatment of migraine with compounds targeting specific molecular mechanisms.
- Published
- 2022
- Full Text
- View/download PDF
11. Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
- Author
-
Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Florindo d’Onofrio, Maria Albanese, Ilaria Cetta, Paola Di Fiore, Maurizio Zucco, Massimo FilippiBonassi, Francesco Bono, Claudia Altamura, Stefania Proietti, Stefano Bonassi, Fabrizio Vernieri, and for the FRIEND-Study Group
- Subjects
Fremanezumab ,Migraine treatment ,CGRP monoclonal antibody ,Real-world ,Predictor ,Medicine - Abstract
Abstract Background Fremanezumab has demonstrated to be effective, safe, and tolerated in the prevention of episodic or chronic migraine (CM) in randomized, placebo-controlled trials (RCTs). Real-life studies are needed to explore drug effects in unselected patients in routine circumstances and to provide higher generalizability results. This study explores the effectiveness, safety, and tolerability of fremanezumab in a real-life population of individuals affected by high-frequency episodic (HFEM: 8–14 days/month) or CM. Methods This is a 12-week multicenter, prospective, cohort, real-life study. We considered all consecutive patients affected by HFEM or CM visited at 9 Italian headache centers from 28/07/2020 to 11/11/2020. Eligible patients were given subcutaneous fremanezumab at the doses of 225 mg monthly or 675 mg quarterly, according to their preference. Primary study endpoints were the change in monthly migraine days (MMDs) in HFEM and monthly headache days (MHDs) in CM patients at weeks 9–12 compared to baseline. Secondary endpoints encompassed variation in monthly analgesic intake (MAI), Numerical Rating Scale (NRS), HIT-6 and MIDAS scores, and ≥ 50%, ≥ 75% and 100% responder rates at the same time intervals. Results Sixty-seventh number migraine patients had received ≥ 1 subcutaneous fremanezumab dose and were considered for safety analysis, while 53 patients completed 12 weeks of treatment and were included also in the effectiveness analysis. Fremanezumab was effective in both HFEM and CM, inducing at week 12 a significant reduction in MMDs (-4.6, p
- Published
- 2022
- Full Text
- View/download PDF
12. Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients
- Author
-
Barbanti, Piero, Egeo, Gabriella, Aurilia, Cinzia, Altamura, Claudia, d’Onofrio, Florindo, Finocchi, Cinzia, Albanese, Maria, Aguggia, Marco, Rao, Renata, Zucco, Maurizio, Frediani, Fabio, Filippi, Massimo, Messina, Roberta, Cevoli, Sabina, Carnevale, Antonio, Fiorentini, Giulia, Messina, Stefano, Bono, Francesco, Torelli, Paola, Proietti, Stefania, Bonassi, Stefano, and Vernieri, Fabrizio
- Published
- 2022
- Full Text
- View/download PDF
13. Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
- Author
-
Barbanti, Piero, Egeo, Gabriella, Aurilia, Cinzia, d’Onofrio, Florindo, Albanese, Maria, Cetta, Ilaria, Di Fiore, Paola, Zucco, Maurizio, Filippi, Massimo, Bono, Francesco, Altamura, Claudia, Proietti, Stefania, Bonassi, Stefano, and Vernieri, Fabrizio
- Published
- 2022
- Full Text
- View/download PDF
14. Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study
- Author
-
Ornello, Raffaele, Baraldi, Carlo, Guerzoni, Simona, Lambru, Giorgio, Andreou, Anna P., Raffaelli, Bianca, Gendolla, Astrid, Barbanti, Piero, Aurilia, Cinzia, Egeo, Gabriella, Cevoli, Sabina, Favoni, Valentina, Vernieri, Fabrizio, Altamura, Claudia, Russo, Antonio, Silvestro, Marcello, Valle, Elisabetta Dalla, Mancioli, Andrea, Ranieri, Angelo, Alfieri, Gennaro, Latysheva, Nina, Filatova, Elena, Talbot, Jamie, Cheng, Shuli, Holle, Dagny, Scheffler, Armin, Nežádal, Tomáš, Čtrnáctá, Dana, Šípková, Jitka, Matoušová, Zuzana, Casalena, Alfonsina, Maddestra, Maurizio, Viola, Stefano, Affaitati, Giannapia, Giamberardino, Maria Adele, Pistoia, Francesca, Reuter, Uwe, and Sacco, Simona
- Published
- 2022
- Full Text
- View/download PDF
15. Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
- Author
-
Barbanti, Piero, Egeo, Gabriella, Aurilia, Cinzia, d’Onofrio, Florindo, Albanese, Maria, Cetta, Ilaria, Di Fiore, Paola, Zucco, Maurizio, Filippi, Massimo, Bono, Francesco, Altamura, Claudia, Proietti, Stefania, Bonassi, Stefano, and Vernieri, Fabrizio
- Published
- 2022
- Full Text
- View/download PDF
16. Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
- Author
-
Barbanti, Piero, Egeo, Gabriella, Aurilia, Cinzia, d’Onofrio, Florindo, Albanese, Maria, Cetta, Ilaria, Di Fiore, Paola, Zucco, Maurizio, Filippi, Massimo, Bono, Francesco, Altamura, Claudia, Proietti, Stefania, Bonassi, Stefano, and Vernieri, Fabrizio
- Published
- 2022
- Full Text
- View/download PDF
17. Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study
- Author
-
Raffaele Ornello, Carlo Baraldi, Simona Guerzoni, Giorgio Lambru, Anna P. Andreou, Bianca Raffaelli, Astrid Gendolla, Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, Sabina Cevoli, Valentina Favoni, Fabrizio Vernieri, Claudia Altamura, Antonio Russo, Marcello Silvestro, Elisabetta Dalla Valle, Andrea Mancioli, Angelo Ranieri, Gennaro Alfieri, Nina Latysheva, Elena Filatova, Jamie Talbot, Shuli Cheng, Dagny Holle, Armin Scheffler, Tomáš Nežádal, Dana Čtrnáctá, Jitka Šípková, Zuzana Matoušová, Alfonsina Casalena, Maurizio Maddestra, Stefano Viola, Giannapia Affaitati, Maria Adele Giamberardino, Francesca Pistoia, Uwe Reuter, and Simona Sacco
- Subjects
Erenumab ,Treatment efficacy ,Migraine frequency ,Real-world ,Medicine - Abstract
Abstract Background Monoclonal antibodies acting on the calcitonin gene-related peptide (CGRP) or its receptor have changed migraine preventive treatment. Those treatments have led to reconsidering the outcomes of migraine prevention. Available data mostly considered benefits in terms of relative efficacy (percent or absolute decrease in monthly migraine days [MMDs] or headache days compared with baseline). However, not enough attention has been paid to residual MMDs and/or migraine-related disability in treated patients. In the present study, we aimed at comparing the relative and absolute efficacy of erenumab. Methods ESTEEMen was a collaborative project among 16 European headache centers which already performed real-life data collections on patients treated with erenumab for at least 12 weeks. For the present study, we performed a subgroup analysis on patients with complete data on MMDs at baseline and at weeks 9-12 of treatment. Starting from efficacy thresholds proposed by previous literature, we classified patients into 0-29%, 30-49%, 50-74%, and ≥75% responders according to MMD decrease from baseline to weeks 9-12 of treatment. For each response category, we reported the median MMDs and Headache Impact test-6 (HIT-6) scores at baseline and at weeks 9-12. We categorized the number of residual MMDs at weeks 9-12 as follows: 0-3, 4-7, 8-14, ≥15. We classified HIT-6 score into four categories: ≤49, 50-55, 56-59, and ≥60. To keep in line with the original scope of the ESTEEMen study, calculations were performed in men and women. Results Out of 1215 patients, at weeks 9-12, 381 (31.4%) had a 0-29% response, 186 (15.3%) a 30-49% response, 396 (32.6%) a 50-74% response, and 252 (20.7%) a ≥75% response; 246 patients (20.2%) had 0-3 residual MMDs, 443 (36.5%) had 4-7 MMDs, 299 (24.6%) had 8-14 MMDs, and 227 (18.7%) had ≥15 MMDs. Among patients with 50-74% response, 246 (62.1%) had 4-7 and 94 (23.7%) 8-14 residual MMDs, while among patients with ≥75% response 187 (74.2%) had 0-3 and 65 (25.8%) had 4-7 residual MMDs. Conclusions The present study shows that even patients with good relative response to erenumab may have a clinically non-negligible residual migraine burden. Relative measures of efficacy cannot be enough to thoroughly consider the efficacy of migraine prevention.
- Published
- 2022
- Full Text
- View/download PDF
18. Evaluating the Effectiveness, Tolerability, and Safety of Eptinezumab in High-Frequency and Chronic Migraine in Real World: EMBRACE—The First Italian Multicenter, Prospective, Real-Life Study.
- Author
-
Barbanti, Piero, Orlando, Bianca, Egeo, Gabriella, d'Onofrio, Florindo, Doretti, Alberto, Messina, Stefano, Autunno, Massimo, Messina, Roberta, Filippi, Massimo, Fiorentini, Giulia, Rotondi, Cristina, Bonassi, Stefano, and Aurilia, Cinzia
- Subjects
IMPACT testing ,MIGRAINE ,PEPTIDES ,TREATMENT failure ,CONTENT analysis - Abstract
We conducted a multicenter, prospective study (EMBRACE) evaluating the real-life effectiveness, safety, and tolerability of eptinezumab (100 mg/300 mg)—a monoclonal antibody targeting the calcitonin-gene-related peptide (anti-CGRP mAb)—in high-frequency episodic migraine (HFEM) or chronic migraine (CM). The primary endpoint was the change in monthly migraine days (MMD) for HFEM or monthly headache days (MHD) for CM at weeks 9–12 compared to baseline. The secondary endpoints included changes in monthly analgesic intake (MAI), Numerical Rating Scale (NRS), Headache Impact Test (HIT-6), Migraine Disability Assessment Scale (MIDAS), Migraine Interictal Burden Scale (MIBS-4), and responder rates. The safety analysis involved 44 subjects; the effectiveness analysis included 26 individuals. Eptinezumab was well-tolerated. In CM patients, eptinezumab significantly reduced MHD (−16.1 ± 9.9, p < 0.001), MAI, NRS, HIT-6, MIDAS, and MIBS-4. In HFEM patients, it significantly reduced NRS, HIT-6, MIDAS, and MIBS-4, though reductions in MMD (−3.3 ± 4.5) and MAI were not statistically significant. Overall, ≥50% and ≥75% response rates were 61.5% and 30.8%, respectively (60% and 30% in non-responders to subcutaneous anti-CGRP mAbs). The clinical change was rated as much or very much improved by 61.0% of the patients. Eptinezumab demonstrated high effectiveness, safety, and tolerability in real-life among hard-to-treat migraine patients with multiple treatment failures, including anti-CGRP mAbs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study
- Author
-
Fabrizio Vernieri, Nicoletta Brunelli, Roberta Messina, Carmelina Maria Costa, Bruno Colombo, Paola Torelli, Simone Quintana, Sabina Cevoli, Valentina Favoni, Florindo d’Onofrio, Gabriella Egeo, Renata Rao, Massimo Filippi, Piero Barbanti, and Claudia Altamura
- Subjects
Calcitonin gene-related peptide ,Monoclonal antibodies ,Migraine treatment ,Real-world ,Discontinuation ,Medicine - Abstract
Abstract Background Monoclonal antibodies anti-calcitonin gene-related peptide (mAbs anti-CGRP) pathway are effective and safe on migraine prevention. However, some drug agencies limited these treatments to one year due to their high costs. This study aimed at evaluating the effect of discontinuing mAbs anti-CGRP on monthly migraine days (MMDs) and disability in high-frequency episodic (HFEM) and chronic migraine (CM) patients. Methods This observational longitudinal cohort study was conducted at 10 Italian headache centres. Consecutive adult patients were followed-up for three months (F-UP1–3) after discontinuation of a one-year erenumab/galcanezumab treatment. The primary endpoint was the change in F-UP MMDs. Secondary endpoints included variation in pain intensity (Numerical Rating Scale, NRS), monthly acute medication intake (MAMI), and HIT-6 scores. We also assessed from F-UP1 to 3 the ≥50% response rate, relapse rate to CM, and recurrence of Medication Overuse (MO). Results We enrolled 154 patients (72.1% female, 48.2 ± 11.1 years, 107 CM, 47 HFEM); 91 were treated with erenumab, 63 with galcanezumab. From F-UP1 to F-UP3, MMDs, MAMI, NRS, and HIT-6 progressively increased but were still lower at F-UP3 than baseline (Friedman’s analysis of rank, p
- Published
- 2021
- Full Text
- View/download PDF
20. Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
- Author
-
Fabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, Carmelina Maria Costa, Cinzia Aurilia, Gabriella Egeo, Luisa Fofi, Valentina Favoni, Giulia Pierangeli, Carlo Lovati, Marco Aguggia, Florindo d’Onofrio, Alberto Doretti, Paola Di Fiore, Cinzia Finocchi, Renata Rao, Francesco Bono, Angelo Ranieri, Maria Albanese, Sabina Cevoli, Piero Barbanti, and for the GARLIT Study Group
- Subjects
Calcitonin gene-related peptide ,Monoclonal antibodies ,Migraine treatment ,Real world ,Medicine - Abstract
Abstract Background The clinical benefit of galcanezumab, demonstrated in randomized clinical trials (RCTs), remains to be quantified in real life. This study aimed at evaluating the effectiveness, safety and tolerability of galcanezumab in the prevention of high-frequency episodic migraine (HFEM) and chronic migraine (CM) in a real-life setting. Methods This multicenter prospective observational cohort study was conducted between November 2019 and January 2021 at 13 Italian headache centers. Consecutive adult HFEM and CM patients clinically eligible were enrolled and treated with galcanezumab subcutaneous injection 120 mg monthly with the first loading dose of 240 mg. The primary endpoint was the change in monthly migraine days (MMDs) in HFEM and monthly headache days (MHDs) in CM patients after 6 months of therapy (V6). Secondary endpoints were the Numerical Rating Scale (NRS), monthly painkiller intake (MPI), HIT-6 and MIDAS scores changes, ≥50% responder rates (RR), the conversion rate from CM to episodic migraine (EM) and Medication Overuse (MO) discontinuation. Results One hundred sixty-three patients (80.5% female, 47.1 ± 11.7 years, 79.8% CM) were included. At V6, MMDs reduced by 8 days in HFEM and MHDs by 13 days in CM patients (both p
- Published
- 2021
- Full Text
- View/download PDF
21. Machine learning approach to predict medication overuse in migraine patients
- Author
-
Ferroni, Patrizia, Zanzotto, Fabio M., Scarpato, Noemi, Spila, Antonella, Fofi, Luisa, Egeo, Gabriella, Rullo, Alessandro, Palmirotta, Raffaele, Barbanti, Piero, and Guadagni, Fiorella
- Published
- 2020
- Full Text
- View/download PDF
22. Machine learning approach to predict medication overuse in migraine patients
- Author
-
Patrizia Ferroni, Fabio M. Zanzotto, Noemi Scarpato, Antonella Spila, Luisa Fofi, Gabriella Egeo, Alessandro Rullo, Raffaele Palmirotta, Piero Barbanti, and Fiorella Guadagni
- Subjects
Migraine ,Medication overuse ,Artificial intelligence ,Machine learning ,Decision support systems ,Biotechnology ,TP248.13-248.65 - Abstract
Machine learning (ML) is largely used to develop automatic predictors in migraine classification but automatic predictors for medication overuse (MO) in migraine are still in their infancy. Thus, to understand the benefits of ML in MO prediction, we explored an automated predictor to estimate MO risk in migraine. To achieve this objective, a study was designed to analyze the performance of a customized ML-based decision support system that combines support vector machines and Random Optimization (RO-MO). We used RO-MO to extract prognostic information from demographic, clinical and biochemical data. Using a dataset of 777 consecutive migraine patients we derived a set of predictors with discriminatory power for MO higher than that observed for baseline SVM. The best four were incorporated into the final RO-MO decision support system and risk evaluation on a five-level stratification was performed. ROC analysis resulted in a c-statistic of 0.83 with a sensitivity and specificity of 0.69 and 0.87, respectively, and an accuracy of 0.87 when MO was predicted by at least three RO-MO models. Logistic regression analysis confirmed that the derived RO-MO system could effectively predict MO with ORs of 5.7 and 21.0 for patients classified as probably (3 predictors positive), or definitely at risk of MO (4 predictors positive), respectively. In conclusion, a combination of ML and RO – taking into consideration clinical/biochemical features, drug exposure and lifestyle – might represent a valuable approach to MO prediction in migraine and holds the potential for improving model precision through weighting the relative importance of attributes.
- Published
- 2020
- Full Text
- View/download PDF
23. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study
- Author
-
Vernieri, Fabrizio, Brunelli, Nicoletta, Messina, Roberta, Costa, Carmelina Maria, Colombo, Bruno, Torelli, Paola, Quintana, Simone, Cevoli, Sabina, Favoni, Valentina, d’Onofrio, Florindo, Egeo, Gabriella, Rao, Renata, Filippi, Massimo, Barbanti, Piero, and Altamura, Claudia
- Published
- 2021
- Full Text
- View/download PDF
24. Association of LTA and SOD Gene Polymorphisms with Cerebral White Matter Hyperintensities in Migraine Patients
- Author
-
Patrizia Ferroni, Raffaele Palmirotta, Gabriella Egeo, Cinzia Aurilia, Maria Giovanna Valente, Antonella Spila, Alberto Pierallini, Piero Barbanti, and Fiorella Guadagni
- Subjects
inflammation ,oxidant stress ,migraine ,lymphotoxin α ,superoxide dismutase ,genetic variants ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
White matter hyperintensities (WMHs) in migraine could be related to inflammatory and antioxidant events. The aim of this study is to verify whether migraine patients with WMHs carry a genetic pro-inflammatory/pro-oxidative status. To test this hypothesis, we analyzed lymphotoxin alpha (LTA; rs2071590T and rs2844482G) and superoxide dismutase 1 (SOD1; rs2234694C) and 2 (SOD2; rs4880T) gene polymorphisms (SNPs) in 370 consecutive patients affected by episodic (EM; n = 251) and chronic (CM; n = 119) migraine and in unrelated healthy controls (n = 100). Brain magnetic resonance was available in 183/370 patients. The results obtained show that genotypes and allele frequencies for all tested SNPs did not differ between patients and controls. No association was found between single SNPs or haplotypes and sex, migraine type, cardiovascular risk factors or disorders. Conversely, the LTA rs2071590T (OR = 2.2) and the SOD1 rs2234694C (OR = 4.9) alleles were both associated with WMHs. A four-loci haplotype (TGCT haplotype: rs2071590T/rs2844482G/rs2234694C/rs4880T) was significantly more frequent in migraineurs with WMHs (7 of 38) compared to those without WMHs (4 of 134; OR = 8.7). We may, therefore, conclude by suggesting that that an imbalance between pro-inflammatory/pro-oxidative and antioxidant events in genetically predisposed individuals may influence the development of WMHs.
- Published
- 2022
- Full Text
- View/download PDF
25. Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
- Author
-
Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Florindo d’Onofrio, Maria Albanese, Ilaria Cetta, Paola Di Fiore, Maurizio Zucco, Massimo Filippi, Francesco Bono, Claudia Altamura, Stefania Proietti, Stefano Bonassi, Fabrizio Vernieri, and for the FRIEND-Study Group
- Subjects
Medicine - Published
- 2022
- Full Text
- View/download PDF
26. Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
- Author
-
Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Florindo d’Onofrio, Maria Albanese, Ilaria Cetta, Paola Di Fiore, Maurizio Zucco, Massimo Filippi, Francesco Bono, Claudia Altamura, Stefania Proietti, Stefano Bonassi, Fabrizio Vernieri, and and for the FRIEND-Study Group
- Subjects
Medicine - Published
- 2022
- Full Text
- View/download PDF
27. Botulinum Neurotoxin for the Treatment of Neuropathic Pain
- Author
-
Gabriella Egeo, Luisa Fofi, and Piero Barbanti
- Subjects
botulinum toxin ,neuropathic pain ,pain treatments ,visual analog scale ,disability ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Botulinum neurotoxin is widely used for the treatment of central and peripherical neurological conditions. Initially used to treat strabismus, over the years its use has been expanded also to spasticity and other neurological disorders. This review summarizes the evidence from the published literature regarding its effect on neuropathic pain. Almost all investigations were performed using onabotulinum toxin type A (BoNT/A). Most studies provided positive results, even though toxin formulation, dose, dilution, injection techniques, and sites are heterogeneous across studies. Future larger, high-quality, specifically designed clinical trials are warranted to confirm botulinum neurotoxin efficacy in neuropathic pain.
- Published
- 2020
- Full Text
- View/download PDF
28. Long‐term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high‐frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study
- Author
-
Barbanti P., Aurilia C., Cevoli S., Egeo G., Fofi L., Messina R., Salerno A., Torelli P., Albanese M., Carnevale A., Bono F., D'Amico D., Filippi M., Altamura C., Vernieri F., Colombo B., Frediani F., Mercuri B., D'Onofrio F., Grazzi L., Aguggia M., Pierangeli G., Favoni V., Finocchi C., Di Fiore P., Costa C. M., Brunelli N., Fallacara A., Bertuzzo D., Zucco M., Di Clemente L., Trimboli M., Pascarella A., Manzo L., Barbanti P., Aurilia C., Cevoli S., Egeo G., Fofi L., Messina R., Salerno A., Torelli P., Albanese M., Carnevale A., Bono F., D'Amico D., Filippi M., Altamura C., Vernieri F., Colombo B., Frediani F., Mercuri B., D'Onofrio F., Grazzi L., Aguggia M., Pierangeli G., Favoni V., Finocchi C., Di Fiore P., Costa C.M., Brunelli N., Fallacara A., Bertuzzo D., Zucco M., Di Clemente L., Trimboli M., Pascarella A., Manzo L., Barbanti, Piero, Aurilia, Cinzia, Cevoli, Sabina, Egeo, Gabriella, Fofi, Luisa, Messina, Roberta, Salerno, Antonio, Torelli, Paola, Albanese, Maria, Carnevale, Antonio, Bono, Francesco, D'Amico, Domenico, Filippi, Massimo, Altamura, Claudia, and Vernieri, Fabrizio
- Subjects
Adult ,Male ,Calcitonin Gene-Related Peptide Receptor Antagonist ,medicine.medical_specialty ,Visual analogue scale ,Migraine Disorders ,Population ,Analgesic ,Longitudinal Studie ,Sex Factor ,Calcitonin gene-related peptide ,Antibodies, Monoclonal, Humanized ,calcitonin gene-related peptide ,Sex Factors ,Chronic Migraine ,Migraine Disorder ,Calcitonin Gene-Related Peptide Receptor Antagonists ,Interquartile range ,Internal medicine ,Outcome Assessment, Health Care ,sex ,Humans ,Medicine ,long-term treatment ,migraine ,Longitudinal Studies ,education ,allodynia ,education.field_of_study ,business.industry ,Middle Aged ,medicine.disease ,Italy ,Neurology ,Tolerability ,Migraine ,erenumab ,Hyperalgesia ,Chronic Disease ,Female ,Neurology (clinical) ,business ,Human - Abstract
Objective: To evaluate the long-term effectiveness, safety, and tolerability of erenumab in a real-world migraine population, looking for putative predictors of responsiveness. Background: Erenumab proved to be effective, safe, and well tolerated in the prevention of episodic migraine (EM) and chronic migraine (CM) in long-term extension studies of double-blind, placebo-controlled trials in patients with no more than two (EM) or three (CM) prior preventive treatment failures. Methods: A 48-week, multicenter, longitudinal cohort real-life study was conducted at 15headache centers across eight Italian regions between December 20, 2018 and July 31, 2020. We considered all consecutive patients with high-frequency episodic migraine (HFEM) or CM aged 18–65years. Each patient was treated with erenumab 70mg, administered monthly. The dose was switched to 140mg in nonresponders and in responders who had become nonresponders for at least 4weeks. Change in monthly migraine days (MMDs) or monthly headache days (MHDs) at Weeks 45–48 compared with baseline was the primary efficacy endpoint. Secondary endpoints encompassed variation in monthly analgesic intake, achievement of a ≥50%, ≥75%, or 100% reduction in migraine or headache days, and any change in the Visual Analogue Scale (VAS) and Headache Impact Test-6 scores (HIT-6) during the same time interval. Results: A total of 242 patients with migraine received at least one dose of erenumab 70mg and were considered for safety analysis, whereas 221 received a monthly erenumab dose for ≥48weeks and were included in the effectiveness and safety analysis set. All patients had previously been treated unsuccessfully with ≥3migraine-preventive medication classes. From baseline to Weeks 45–48, erenumab treatment reduced MMD by 4.3±5.3(mean±SD) in patients with HFEM, and MHD by 12.8±8.9 (mean±SD) in subjects with CM. VAS and HIT-6scores were decreased by 1.8±1.9 (mean±SD) and 12.3±11 (mean±SD) in HFEM, and by 3.0±2.2 (mean±SD) and 13.1±11.2 (mean±SD) in CM. Median monthly analgesic intake passed from 11.0 (interquartile range [IQR] 10.0–13.0) to 5 (IQR 2.0–8.0) in HFEM and from 20.0 (IQR 15.0–30.0) to 6.0 (IQR 3.8–10.0) in CM. The ≥50% responders were 56.1% (32/57) in HFEM and 75.6% (124/164) in CM; ≥75% responders were 31.6% (18/57) and 44.5% (73/164); and 100% responders were 8.8% (5/57) and 1.2% (2/164), respectively. At Week 48, 83.6% (137/164) of patients with CM had reverted to EM. Erenumab was safe and well tolerated. Responsiveness to erenumab was positively associated with cutaneous allodynia (OR: 5.44, 95% CI: 1.52–19.41; p=0.009) in HFEM. In patients with CM, ≥50% responsiveness was positively associated with male sex (OR: 2.99, 95% CI: 1.03–8.7; p=0.044) and baseline migraine frequency (OR: 1.12, 95% CI: 1.05–1.20; p=0.001) and negatively associated with psychiatric comorbidities (OR: 0.37, 95% CI: 0.15–0.87; p=0.023) and prior treatment failures (OR: 0.77, 95% CI: 0.64–0.92; p=0.004). Conclusions: Long-term (48-week) erenumab treatment provides sustained effectiveness, safety, and tolerability in real-life patients with HFEM or CM with ≥3 prior preventive treatment failures. The dose of 140mg was required in most patients along the study and should be taken into consideration as the starting dose. Allodynia (in HFEM), male sex, and baseline migraine frequency (in CM) might represent positive responsiveness predictors. Conversely, psychiatric comorbidities and multiple prior preventive treatment failures could be negative predictors in patients with CM.
- Published
- 2021
29. Applications of Ketogenic Diets in Patients with Headache: Clinical Recommendations
- Author
-
Cherubino Di Lorenzo, Giovanna Ballerini, Piero Barbanti, Andrea Bernardini, Giacomo D’Arrigo, Gabriella Egeo, Fabio Frediani, Riccardo Garbo, Giulia Pierangeli, Maria Pia Prudenzano, Nicoletta Rebaudengo, Grazia Semeraro, Giulio Sirianni, Mariarosaria Valente, Gianluca Coppola, Mackenzie C. Cervenka, and Giovanni Spera
- Subjects
ketogenic diets ,ketosis ,ketones ,clinical recommendations ,headache ,migraine ,Nutrition. Foods and food supply ,TX341-641 - Abstract
Headaches are among the most prevalent and disabling neurologic disorders and there are several unmet needs as current pharmacological options are inadequate in treating patients with chronic headache, and a growing interest focuses on nutritional approaches as non-pharmacological treatments. Among these, the largest body of evidence supports the use of the ketogenic diet (KD). Exactly 100 years ago, KD was first used to treat drug-resistant epilepsy, but subsequent applications of this diet also involved other neurological disorders. Evidence of KD effectiveness in migraine emerged in 1928, but in the last several year’s different groups of researchers and clinicians began utilizing this therapeutic option to treat patients with drug-resistant migraine, cluster headache, and/or headache comorbid with metabolic syndrome. Here we describe the existing evidence supporting the potential benefits of KDs in the management of headaches, explore the potential mechanisms of action involved in the efficacy in-depth, and synthesize results of working meetings of an Italian panel of experts on this topic. The aim of the working group was to create a clinical recommendation on indications and optimal clinical practice to treat patients with headaches using KDs. The results we present here are designed to advance the knowledge and application of KDs in the treatment of headaches.
- Published
- 2021
- Full Text
- View/download PDF
30. Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3‐month observational, longitudinal, cohort, multicenter, Italian real‐life study
- Author
-
Vernieri, Fabrizio, Altamura, Claudia, Brunelli, Nicoletta, Costa, Carmelina Maria, Aurilia, Cinzia, Egeo, Gabriella, Fofi, Luisa, Favoni, Valentina, Lovati, Carlo, Bertuzzo, Davide, d'Onofrio, Florindo, Doretti, Alberto, Di Fiore, Paola, Finocchi, Cinzia, Schiano Di Cola, Francesca, Ranieri, Angelo, Colombo, Bruno, Bono, Francesco, Albanese, Maria, Cevoli, Sabina, Barbanti, Piero, GARLIT Study Group, Filippi, Massimo, Vernieri, Fabrizio, Altamura, Claudia, Brunelli, Nicoletta, Costa, Carmelina Maria, Aurilia, Cinzia, Egeo, Gabriella, Fofi, Luisa, Favoni, Valentina, Lovati, Carlo, Bertuzzo, Davide, D'Onofrio, Florindo, Doretti, Alberto, Di Fiore, Paola, Finocchi, Cinzia, Schiano Di Cola, Francesca, Ranieri, Angelo, Colombo, Bruno, Bono, Francesco, Albanese, Maria, Cevoli, Sabina, Barbanti, Piero, GARLIT Study, Group, and Filippi, Massimo
- Subjects
Adult ,Male ,medicine.medical_specialty ,Migraine Disorders ,Triptans ,Calcitonin gene-related peptide ,Antibodies, Monoclonal, Humanized ,Chronic Migraine ,Double-Blind Method ,Internal medicine ,medicine ,galcanezumab ,Humans ,Mass index ,CGRP ,real-life ,Prospective Studies ,Rapid response ,business.industry ,Middle Aged ,medicine.disease ,Comorbidity ,Treatment Outcome ,Italy ,Neurology ,Migraine ,Female ,Observational study ,monoclonal antibodies ,Neurology (clinical) ,chronic migraine ,business ,medicine.drug - Abstract
Background and purpose A rapid response to preventive therapy is of pivotal importance in severely disabled patients with chronic migraine (CM) and diverse preventive treatment failures. This prospective, observational, multicenter real-life study aimed at investigating the effectiveness of galcanezumab in the first 3 months of treatment of CM patients at 14 Italian headache centers. Methods All consecutive adult patients with CM diagnosis with the clinical indication for galcanezumab were considered. We collected patients' baseline characteristics, monthly headache days, monthly painkiller intake, migraine clinical characteristics, and disability scale scores during a 1-month run-in period (baseline) and the first 3 months of therapy. Possible predictive factors of treatment were considered. Results A total of 156 patients (82.4% female, aged 47.3 +/- 12.3 years) were enrolled. The 65 (41.7%) patients with a consecutive >= 50% response rate (RR) in the 3 months of therapy presented a lower body mass index (p = 0.004) and more frequently presented unilateral migraine pain (p = 0.002) and good response to triptans (p = 0.003). Persistent conversion from CM to episodic migraine was observed in 55.8% (87/156) of patients. They more frequently presented a good response to triptans (p = 0.003) and unilateral pain (p = 0.046). At baseline, 131 of 156 (83.9%) patients presented medication overuse (MO). Of these, 61.8% (81/131) no longer displayed MO consistently during the 3 months. These patients were more frequently responders to triptans (p = 0.002) and less frequently suffered from gastrointestinal comorbidity (p = 0.007). Conclusions Unilateral pain, good response to triptans, and normal weight may be associated with a persistent positive response in the first 3 months of therapy with galcanezumab in CM patients.
- Published
- 2021
31. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study
- Author
-
Simone Quintana, Massimo Filippi, S. Cevoli, Renata Rao, Valentina Favoni, Nicoletta Brunelli, Claudia Altamura, Gabriella Egeo, Carmelina Maria Costa, F. Vernieri, Florindo d’Onofrio, Piero Barbanti, Bruno Colombo, Roberta Messina, Paola Torelli, Vernieri, Fabrizio, Brunelli, Nicoletta, Messina, Roberta, Costa, Carmelina Maria, Colombo, Bruno, Torelli, Paola, Quintana, Simone, Cevoli, Sabina, Favoni, Valentina, D’Onofrio, Florindo, Egeo, Gabriella, Rao, Renata, Filippi, Massimo, Barbanti, Piero, and Altamura, Claudia
- Subjects
Adult ,Male ,Oncology ,medicine.medical_specialty ,medicine.drug_class ,Migraine Disorders ,Discontinuation ,Calcitonin gene-related peptide ,Monoclonal antibody ,Migraine treatment ,Internal medicine ,Headache Disorders, Secondary ,medicine ,Humans ,Longitudinal Studies ,Longitudinal cohort ,business.industry ,Antibodies, Monoclonal ,General Medicine ,Middle Aged ,Anesthesiology and Pain Medicine ,Italy ,Real-world ,Medicine ,Female ,Observational study ,Monoclonal antibodies ,Neurology (clinical) ,business - Abstract
Background Monoclonal antibodies anti-calcitonin gene-related peptide (mAbs anti-CGRP) pathway are effective and safe on migraine prevention. However, some drug agencies limited these treatments to one year due to their high costs. This study aimed at evaluating the effect of discontinuing mAbs anti-CGRP on monthly migraine days (MMDs) and disability in high-frequency episodic (HFEM) and chronic migraine (CM) patients. Methods This observational longitudinal cohort study was conducted at 10 Italian headache centres. Consecutive adult patients were followed-up for three months (F-UP1–3) after discontinuation of a one-year erenumab/galcanezumab treatment. The primary endpoint was the change in F-UP MMDs. Secondary endpoints included variation in pain intensity (Numerical Rating Scale, NRS), monthly acute medication intake (MAMI), and HIT-6 scores. We also assessed from F-UP1 to 3 the ≥50% response rate, relapse rate to CM, and recurrence of Medication Overuse (MO). Results We enrolled 154 patients (72.1% female, 48.2 ± 11.1 years, 107 CM, 47 HFEM); 91 were treated with erenumab, 63 with galcanezumab. From F-UP1 to F-UP3, MMDs, MAMI, NRS, and HIT-6 progressively increased but were still lower at F-UP3 than baseline (Friedman’s analysis of rank, p p = .032). Of the 84 baseline CM patients who had reverted to episodic migraine, 28 (33.3%) relapsed to CM at F-UP1, 35 (41.7%) at F-UP2, 39 (46.4%) at F-UP3. Of the 64 baseline patients suffering of medication overuse headache ceasing MO, 15 (18.3%) relapsed to MO at F-UP1, 26 (31.6%) at F-UP2, and 30 (42.3%, 11 missing data) at F-UP3. Lower MMDs, MAMI, NRS, and HIT-6 and higher response rate in the last month of therapy characterized patients with ≥50% response rate at F-UP1 and F-UP3 (Mann-Whitney U test; consistently p Conclusion Migraine frequency and disability gradually increased after mAbs anti-CGRP interruption. Most patients did not relapse to MO or CM despite the increase in MMDs. Our data suggest to reconsider mAbs anti-CGRP discontinuation.
- Published
- 2021
32. The first report of the Italian Migraine Registry (I-GRAINE)
- Author
-
Barbanti, Piero, Egeo, Gabriella, Aurilia, Cinzia, Fiorentini, Giulia, Proietti, Stefania, Tomino, Carlo, Bonassi, Elena, StefanoCollaborations:The first report of the Italian Migraine Registry (I-GRAINE): Maria Albanese, Allais, GIOVANNI BATTISTA, Claudia, Altamura, Marco, Aguggia, Massimo, Autunno, Patrizia, Balsamo, Marco, Bartoli, Maria, Bloise, Benedetto, Chiara, Francesco, Bono, Giovanni, Caggia, Cecilia, Camarda, Antonio, Carnevale, Alessandra, Cerchi, Barbanti, Piero, Egeo, Gabriella, Aurilia, Cinzia, Fiorentini, Giulia, Proietti, Stefania, Tomino, Carlo, Bonassi, Stefano, Cecilia , camarda, Bonassi, Stefano, Italian Migraine Registry Study, Group, and Filippi, Massimo
- Subjects
Male ,Registry ,Healthcare resource use ,Migraine Disorders ,Headache ,Migraine ,Patient’s journey ,Treatment ,Dermatology ,General Medicine ,Tryptamines ,Psychiatry and Mental health ,Humans ,Settore MED/26 - Neurologia ,Female ,Neurology (clinical) ,Prospective Studies ,Registries - Abstract
Italian Migraine Registry (I-GRAINE) is a multicenter (n = 38), prospective, observational, non-interventional study aimed at providing big data on migraine to ensure proper clinical disease management, according to scientific, and sustainability criteria. We enrolled consecutive patients affected by episodic or chronic migraine according to the systematic random method. Information on sociodemographic characteristics, lifestyle, migraine features, patient's journey, and healthcare resource use were gathered using face-to-face interviews.On the date of 31 December 2021, we enrolled 231 patients at 12 headache centers. Most of them were women (84.4%), with high migraine frequency (9.6 +/- 6.9 days/month) and severe disability (MIDAS score: 43.0 +/- 40.8; HIT-6 score: 60.4 +/- 10.6). Only a minority of patients (38.1%) had previously visited a headache center.A clear-cut difference emerged in the proportion of responders to nonspecific acute treatments (43.5-66.7%) compared to triptans (76.3%) and in responders to unspecific prophylaxis (5.4-35%) compared to anti-CGRP monoclonal antibodies (69.2-78.6%). Most patients underwent >= 1 specialist visit (66.9%) or diagnostic investigation (77.4%) over the last 3 years-mostly subsidized by our national health system-inappropriate in 64.9% and 25% of the cases, respectively.The I-GRAINE registry is expected to provide a large and exponentially increasing collection of clinical, biological, and epidemiologic information and will contribute to moving migraine out of the shadow cone of marginalization, which has been often relegated up to now.
- Published
- 2022
33. Association of LTA and SOD Gene Polymorphisms with Cerebral White Matter Hyperintensities in Migraine Patients
- Author
-
Ferroni, Patrizia, primary, Palmirotta, Raffaele, additional, Egeo, Gabriella, additional, Aurilia, Cinzia, additional, Valente, Maria Giovanna, additional, Spila, Antonella, additional, Pierallini, Alberto, additional, Barbanti, Piero, additional, and Guadagni, Fiorella, additional
- Published
- 2022
- Full Text
- View/download PDF
34. Non-invasive Vagus Nerve Stimulation (nVNS) as mini-prophylaxis for menstrual/menstrually related migraine: an open-label study
- Author
-
Grazzi, Licia, Egeo, Gabriella, Calhoun, Anne H., McClure, Candace K., Liebler, Eric, and Barbanti, Piero
- Published
- 2016
- Full Text
- View/download PDF
35. Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study
- Author
-
Francesco Bono, Piero Barbanti, Fabrizio Vernieri, Gabriella Egeo, Bruno Mercuri, Massimo Filippi, Cinzia Aurilia, Antonio Salerno, Licia Grazzi, Sabina Cevoli, Fabio Frediani, Antonio Carnevale, Bruno Colombo, Luisa Fofi, Claudia Altamura, Barbanti, P., Aurilia, C., Egeo, G., Fofi, L., Cevoli, S., Colombo, B., Filippi, M., Frediani, F., Bono, F., Grazzi, L., Salerno, A., Mercuri, B., Carnevale, A., Altamura, C., and Vernieri, F.
- Subjects
Adult ,Male ,medicine.medical_specialty ,Visual analogue scale ,Migraine Disorders ,Population ,Effectiveness ,Antibodies, Monoclonal, Humanized ,03 medical and health sciences ,0302 clinical medicine ,Chronic Migraine ,Cost of Illness ,Calcitonin Gene-Related Peptide Receptor Antagonists ,Interquartile range ,Internal medicine ,Outcome Assessment, Health Care ,medicine ,Clinical endpoint ,Humans ,Prospective Studies ,030212 general & internal medicine ,education ,Migraine ,Pain Measurement ,education.field_of_study ,business.industry ,Real-life ,Middle Aged ,medicine.disease ,Treatment ,Italy ,Neurology ,Tolerability ,Calcitonin gene-related peptide ,Cohort ,Female ,Neurology (clinical) ,business ,030217 neurology & neurosurgery ,Erenumab - Abstract
Objective: To assess the effectiveness, safety, and tolerability of erenumab in a real-life migraine population, while trying to identify responsiveness predictors. Background: Erenumab is a fully human Ig-2 monoclonal antibody blocking the calcitonin gene-related peptide receptor, indicated for migraine prophylaxis. Phase II and III trials demonstrated that erenumab is effective, safe, and well tolerated in the prevention of episodic and chronic migraine (CM), showing an early onset of action. Methods: This is a multicenter, prospective, cohort, and real-life study. We considered for enrolment all consecutive patients aged 18–65 affected by high-frequency episodic migraine (HFEM) or CM, with or without medication overuse, visited at nine Italian Headache Centers from December 20, 2018 to September 30, 2019. Each patient was treated with erenumab 70mg, administered subcutaneously every 4weeks. Treatment duration was planned to last from 6 to 12months, depending on the patient's response. The primary endpoint was the change in monthly migraine days (MMDs) at weeks 9–12 compared to baseline. Secondary endpoints included changes in monthly analgesics intake, ≥50%, ≥75%, and 100% responder rates and any variation in the Visual Analog Scale (VAS) and Headache Impact Test scores (HIT). Results: In total, 372 migraine patients were treated with at least one dose of erenumab 70mg. At weeks 9–12, erenumab decreased MMDs by 4.5±4.1days (mean±SD) in patients with HFEM and by 9.3±9.1 (mean±SD) days in those with CM compared to baseline. At weeks 9–12 VAS score was reduced by 1.9±1.9 (mean±SD), HIT score by 10.7±8.8 (mean±SD), and median monthly analgesics intake passed from 12.0 (interquartile range [IQR] 10.0–14.0) to 5.0 (IQR 3.0–7.0) in HFEM. In CM patients, VAS was reduced by 1.7±2.0 (mean±SD), HIT by 9.7±10.4 (mean±SD), and median monthly analgesics intake passed from 20.0 (IQR 15.0–30.0) to 8.0 (IQR 5.0–15.0). At week 12, ≥50% responders were 60/101 (59.4%) for HFEM and 146/263 (55.5%) for CM, ≥75% responders were 17/101 (16.8%) and 59/263 (22.4%) and 100% responders 1/101 (1.0%) and 3/263 (1.1%), respectively. Erenumab responsiveness in HFEM was positively associated with unilateral pain localization (OR: 3.03, 95% CI: 1.24–7.40; p=0.015), whereas in CM responsiveness was positively associated with and baseline migraine frequency (OR: 1.06, 95% CI:1.02–1.11; p=0.031), dopaminergic symptoms (OR: 2.01, 95% CI: 1.14–3.52; p=0.015), and negatively associated with psychiatric comorbidities (OR: 0.43, 95% CI: 0.20–0.93; p=0.003). Conclusions: Erenumab 70mg is effective, safe, and well tolerated in real life. Easily obtainable clinical features might be of help in predicting patient's responsiveness.
- Published
- 2020
36. Locking down the CGRP pathway during the COVID-19 pandemic lockdown: the PandeMig study
- Author
-
Adriana Fallacara, Sabina Cevoli, Paola Torelli, Claudia Altamura, Gabriella Egeo, Piero Barbanti, Giulia Pierangeli, Cinzia Aurilia, Fabrizio Vernieri, Umberto Pensato, Nicoletta Brunelli, Luisa Fofi, Valentina Favoni, Altamura C., Cevoli S., Aurilia C., Egeo G., Fofi L., Torelli P., Brunelli N., Pierangeli G., Favoni V., Fallacara A., Pensato U., Barbanti P., and Vernieri F.
- Subjects
Male ,Neurology ,Longitudinal Studie ,Cohort Studies ,0302 clinical medicine ,Migraine Disorder ,Surveys and Questionnaires ,Pandemic ,Longitudinal Studies ,030212 general & internal medicine ,CGRP ,General Medicine ,Middle Aged ,Psychiatry and Mental health ,Italy ,Cohort ,Quarantine ,Female ,Neurosurgery ,Coronavirus Infections ,Cohort study ,Human ,Adult ,medicine.medical_specialty ,Calcitonin Gene-Related Peptide Receptor Antagonist ,Migraine Disorders ,Pneumonia, Viral ,Clinical Neurology ,Dermatology ,Calcitonin gene-related peptide ,Antibodies, Monoclonal, Humanized ,03 medical and health sciences ,Calcitonin Gene-Related Peptide Receptor Antagonists ,Internal medicine ,medicine ,Humans ,Pandemics ,Migraine ,business.industry ,Coronavirus Infection ,COVID-19 ,medicine.disease ,Galcanezumab ,Presenteeism ,Neurology (clinical) ,Cohort Studie ,business ,030217 neurology & neurosurgery ,Erenumab - Abstract
Objectives: The COVID-19 pandemic and the consequent lockdown came as a storm disrupting people’s everyday life. This study aimed at observing whether the COVID-19 related lockdown influenced migraine frequency and disability in migraine patients on therapy with monoclonal antibodies inhibiting the CGRP pathway. Methods: In this longitudinal observational cohort study, 147 consecutive patients receiving monthly administration of erenumab or galcanezumab were enrolled in four Italian headache centers. All patients filled a questionnaire concerning working and household settings, recent flu symptoms or COVID-19 diagnosis, and family loss due to COVID-19 infection. Monthly migraine days (MMDs), monthly painkiller intake (MPI), and HIT-6 disability relative to the first month of lockdown imposition (T-lock) and the month before (T-free) were also collected. Results: From T-free to T-lock, the cohort displayed a reduction in MMDs (from 10.5 ± 7.6 to 9.8 ± 7.6, p =.024) and HIT-6 scores (from 59.3 ± 8.3 men reduced MPI more frequently than women (p =.005). Conclusions: Our study observed that the lockdown impact to 57.8 ± 8.8, p=.009), while MPI resulted unchanged (from 11.6 ± 11.5 to 11.1 ± 11.7; p =.114). MMDs, MPI, and HIT-6 variations from T-free to T-lock did not differ according to work settings or household. Patients beyond the first 3 months of therapy presented less often a reduction in MMDs (p =.006) and on everyday life did not affect the migraine load in patients receiving monoclonal antibodies inhibiting the CGRP pathway. Patients in the first months of therapy experienced a greater improvement according to drug pharmacokinetics, while women more frequently needed rescue medications, possibly indicating presenteeism or cephalalgophobia.
- Published
- 2020
37. Look beyond Catechol-O-Methyltransferase genotype for cathecolamines derangement in migraine: the BioBIM rs4818 and rs4680 polymorphisms study
- Author
-
De Marchis, Maria Laura, Barbanti, Piero, Palmirotta, Raffaele, Egeo, Gabriella, Aurilia, Cinzia, Fofi, Luisa, Piroso, Serena, Ialongo, Cristiano, Della-Morte, David, D’Andrea, Giovanni, Ferroni, Patrizia, and Guadagni, Fiorella
- Published
- 2015
- Full Text
- View/download PDF
38. Non-invasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: an open-label study
- Author
-
Barbanti, Piero, Grazzi, Licia, Egeo, Gabriella, Padovan, Anna Maria, Liebler, Eric, and Bussone, Gennaro
- Published
- 2015
- Full Text
- View/download PDF
39. Automated pipeline for the analysis of a scale-reduced steel cable net
- Author
-
Universitat Politècnica de Catalunya. Doctorat en Enginyeria de la Construcció, Universitat Politècnica de Catalunya. Departament d'Enginyeria Civil i Ambiental, Universitat Politècnica de Catalunya. ATEM - Anàlisi i Tecnologia d'Estructures i Materials, Universitat Politècnica de Catalunya. EGEO - Enginyeria Geomàtica, Ramonell Cazador, Carlos, Chacón Flores, Rolando Antonio, Krenn, Burkhard, Puig i Polo, Càrol, Universitat Politècnica de Catalunya. Doctorat en Enginyeria de la Construcció, Universitat Politècnica de Catalunya. Departament d'Enginyeria Civil i Ambiental, Universitat Politècnica de Catalunya. ATEM - Anàlisi i Tecnologia d'Estructures i Materials, Universitat Politècnica de Catalunya. EGEO - Enginyeria Geomàtica, Ramonell Cazador, Carlos, Chacón Flores, Rolando Antonio, Krenn, Burkhard, and Puig i Polo, Càrol
- Abstract
This paper proposes a digitally twinned experimental analysis of a scale-reduced laboratory-sized steel cable net subjected to vertical loading. The test is aimed at establishing automated pipelines of information and analysis between the measurements (displacements of nodes) and the numerical model of the cable net, which are seamlessly interconnected through a BIM model. These automated pipelines erect the frame of the development of a digital twin of the cable net with structural analysis purposes. For the sake of measurements, a terrestrial laser scanner is used. Displacements of the nodes are extracted using computational geometry tools. For the sake of analysis, a data-based numerical model is proposed to obtain the tensile state of the cables. Precisely understanding the force distribution along nets is a challenge at design, construction and operation stages. This research belongs to a vaster project related to the development of automated pipelines of information for European infrastructure in the form of digital twins. The outcome of this laboratory test results is of great use when developing similar automated pipelines of information in real sites including cable nets in roofs., All authors acknowledge the funding of ASHVIN, “Assistants for Healthy, Safe, and Productive Virtual Construction Design, Operation & Maintenance using a Digital Twin” an H2020 project under agreement 958161., Objectius de Desenvolupament Sostenible::9 - Indústria, Innovació i Infraestructura, Postprint (published version)
- Published
- 2022
40. Geometrical digital twinning of a tapered, horizontally curved composite box girder bridge
- Author
-
Universitat Politècnica de Catalunya. Departament d'Enginyeria Civil i Ambiental, Universitat Politècnica de Catalunya. Doctorat en Enginyeria de la Construcció, Universitat Politècnica de Catalunya. ATEM - Anàlisi i Tecnologia d'Estructures i Materials, Universitat Politècnica de Catalunya. EGEO - Enginyeria Geomàtica, Chacón Flores, Rolando Antonio, Ramonell Cazador, Carlos, Puig i Polo, Càrol, Mirambell Arrizabalaga, Enrique, Universitat Politècnica de Catalunya. Departament d'Enginyeria Civil i Ambiental, Universitat Politècnica de Catalunya. Doctorat en Enginyeria de la Construcció, Universitat Politècnica de Catalunya. ATEM - Anàlisi i Tecnologia d'Estructures i Materials, Universitat Politècnica de Catalunya. EGEO - Enginyeria Geomàtica, Chacón Flores, Rolando Antonio, Ramonell Cazador, Carlos, Puig i Polo, Càrol, and Mirambell Arrizabalaga, Enrique
- Abstract
A composite bridge located in the Metropolitan Area of Barcelona represents one of the sites for demonstrating the capabilities of digital twins on maintenance of built assets. Digital twins can be deemed to as digital living replica of the physical one that provides real time information throughout adequate connectivity (sensors, images, remote sensing) and provides automated visualization of the asset for decision-making purposes (performance indicators that are assessed regularly). This demonstrator is an 846 meters long composite bridge with plates and a concrete slab. The plates are tapered along a portion of its length. The bridge is horizontally curved with a bifurcation at its end. One of the challenges in this demonstrator is to reproduce realistically the “as built” shape of the plates using a terrestrial laser scanner for simulation purposes. The outcome of this specific side of the digital twinning (other sides also include many sensor- and image-based methods) is of great interest for maintenance managers. Understanding the real configuration of the asset represents an accurate starting point for subsequent modelling., All authors acknowledge the funding of ASHVIN, “Assistants for Healthy, Safe, and Productive Virtual Construction Design, Operation & Maintenance using a Digital Twin” an H2020 project under agreement 958161., Objectius de Desenvolupament Sostenible::9 - Indústria, Innovació i Infraestructura, Postprint (published version)
- Published
- 2022
41. Ambient modal identification applied to a school building in Girona (Spain)
- Author
-
Universitat Politècnica de Catalunya. Departament de Resistència de Materials i Estructures a l'Enginyeria, Universitat Politècnica de Catalunya. Departament d'Enginyeria Civil i Ambiental, Universitat Politècnica de Catalunya. GIES - Geofísica i Enginyeria Sísmica, Universitat Politècnica de Catalunya. EGEO - Enginyeria Geomàtica, Pujades Beneit, Lluís, González Drigo, José Ramón, Lantada, Nieves, Blázquez Boya, Antoni, Jara Salvador, José Antonio, Universitat Politècnica de Catalunya. Departament de Resistència de Materials i Estructures a l'Enginyeria, Universitat Politècnica de Catalunya. Departament d'Enginyeria Civil i Ambiental, Universitat Politècnica de Catalunya. GIES - Geofísica i Enginyeria Sísmica, Universitat Politècnica de Catalunya. EGEO - Enginyeria Geomàtica, Pujades Beneit, Lluís, González Drigo, José Ramón, Lantada, Nieves, Blázquez Boya, Antoni, and Jara Salvador, José Antonio
- Abstract
The main results of the operational modal analysis of a school building are shown. The building has a four-stories framed-reinforced-concrete structure and it was instrumented with 7 triaxial accelerometers, recording along eight days. Also, specific remote measurements were made with an interferometric radar. The purpose was: i) to monitor periods of activity-inactivity, ii) to identify modal frequencies; iii) to validate a numerical model of the structure and iv) to analyse the feasibility of the radar for remote operational modal analysis. This research allowed us: 1) to quantify clear variations in noise intensity, matching the school activities, 2) to identify the fundamental modes and natural frequencies, which were of 4.4 Hz and 5.4 Hz, in the longitudinal and transversal directions, respectively, 3) to observe slight variations of modal frequencies throughout the day, attributed to the loading/unloading of the building, and at night, attributed to variations in temperature; 4) to confirm the usefulness and suitability of frequency experimental measurements to improve the quality and reliability of building numerical models and, 5) to evaluate the potential of radar measurements for operational modal analysis; radar operates better in tall and flexible buildings, than in rigid ones., José Antonio Jara, of the “Institut Cartogràfic i Geològic de Catalunya”, ICGC, was responsible for the instrumentation of the building and for data collection and storage. The help of Meritxell Nicolau and Josep Soler, secretary and administrator of the “Institut Santa Eugènia” of Girona, Spain, is greatly recognized and acknowledged; they both made possible the accurate instrumentation of the building. Antoni Blázquez, from the Association of Structural Consultants (ACE), provided the plans and documentation of the building. This research has been partially funded by the Spanish Research Agency (AEI) of the Spanish Ministry of Science and Innovation (MICIN) through project with reference: PID2020-117374RB-I00/AEI/10.13039/501100011033, and by the European Regional Development Fund (ERDF) of the European Union (EU) through project with reference EFA158/16/POCRISC (INTERREG/POCTEFA. EU)., Postprint (published version)
- Published
- 2022
42. ¿Cuánto grande es 'grande' en los movimientos de ladera? Encuesta sobre la idea de magnitud y su comunicación
- Author
-
Universitat Politècnica de Catalunya. Doctorat en Enginyeria del Terreny, Universitat Politècnica de Catalunya. EGEO - Enginyeria Geomàtica, Janeras Casanova, Marc, Buxó, Pere, Marturiá Alavedra, Jordi, Barberà, Marcel, Ripoll, Jordi, Universitat Politècnica de Catalunya. Doctorat en Enginyeria del Terreny, Universitat Politècnica de Catalunya. EGEO - Enginyeria Geomàtica, Janeras Casanova, Marc, Buxó, Pere, Marturiá Alavedra, Jordi, Barberà, Marcel, and Ripoll, Jordi
- Abstract
La idea de magnitud de un fenómeno de ladera parece muy evidente, pero sometida a análisis no resulta tan simple. Además, carecemos de una escala de referencia para su valoración cualitativa. Esta indefinición en la magnitud se traslada al concepto de peligrosidad, lo cual dificulta la comunicación, incluso entre técnicos, y más aun con públicos más amplios, quienes resultan imprescindibles aliados para la implementación efectiva de estrategias de mitigación del riesgo. Esta preocupación por la comunicación de la idea de peligrosidad ha orientado en todo momento la elaboración de la guía técnica para la elaboración de Estudios de Identificación de Riesgos Geológicos (EIRG) por parte del ICGC. Esta figura resulta una pieza clave para la consideración de los riesgos geológicos en el urbanismo en Cataluña y hacer efectivo el mandato legislativo en la materia. A raíz de estos trabajos se ha desarrollado una escala de magnitud que pretende ser de la máxima simplicidad y claridad para lograr una comunicación adecuada del riesgo. En esta comunicación pretendemos realizar un test de viabilidad de la escala mediante una encuesta participativa a las personas participantes al simposio., Postprint (published version)
- Published
- 2022
43. Spatial data infrastructure (SDI) for inventory rockfalls with fragmentation information
- Author
-
Universitat Politècnica de Catalunya. Departament d'Enginyeria Civil i Ambiental, Universitat Politècnica de Catalunya. EGEO - Enginyeria Geomàtica, Núñez Andrés, María Amparo, Lantada, Nieves, Martínez llario, Jose, Universitat Politècnica de Catalunya. Departament d'Enginyeria Civil i Ambiental, Universitat Politècnica de Catalunya. EGEO - Enginyeria Geomàtica, Núñez Andrés, María Amparo, Lantada, Nieves, and Martínez llario, Jose
- Abstract
The version of record of this article, first published in Natural Hazards is available online at Publisher's webside: https://doi.org/10.1007/s11069-022-05282-2, The fragmentation phenomenon has a significant effect on rockfall risk assessment. This information is difficult to obtain, but it is key to improving rockfall modelling. For this reason, the RockModels team has gathered data on the fragmentation of several natural events since 2014 that nowadays wants to share them with professionals, academics and stakeholders. The best way for the dissemination of this information is the use of standard or data specifications in order to be interoperable. A fragmentation rockfall database has been created using all the gathered information, according to the INSPIRE Natural Hazard Area Data Specification currently in force. However, new tables have had to be added, since this specification does not consider fragmentation data. There are currently 6000 records of geometries of source areas, envelopes, deposits and mostly individual blocks. A web mapping application, with an automatic function for coordinate reference system transformation, has been created to facilitate access to the spatial database information. All that was developed on open-source software such as OpenLayers JavaScript library, database (PostGre-PostGIS) and the map generating Web Map Service (GeoServer). As more data are collected, the database can be easily updated and the new information will be published. Moreover, to improve data interpretation, a future task is to incorporate 3D models on the web application. The existence of this public database will facilitate research and advance in knowledge of this kind of natural hazards., Peer Reviewed, Postprint (published version)
- Published
- 2022
44. Capturing rockfall kinematic and fragmentation parameters using high-speed camera system
- Author
-
Universitat Politècnica de Catalunya. Doctorat en Enginyeria del Terreny, Universitat Politècnica de Catalunya. Centre Específic de Recerca de Mètodes Numèrics en Ciències Aplicades i Enginyeria, Universitat Politècnica de Catalunya. Departament d'Enginyeria Civil i Ambiental, Universitat Politècnica de Catalunya. EGEO - Enginyeria Geomàtica, Universitat Politècnica de Catalunya. EnGeoModels - Monitoring and Modelling in Engineering Geology, Prades Valls, Albert, Corominas Dulcet, Jordi, Lantada, Nieves, Matas Casado, Gerard, Núñez Andrés, María Amparo, Universitat Politècnica de Catalunya. Doctorat en Enginyeria del Terreny, Universitat Politècnica de Catalunya. Centre Específic de Recerca de Mètodes Numèrics en Ciències Aplicades i Enginyeria, Universitat Politècnica de Catalunya. Departament d'Enginyeria Civil i Ambiental, Universitat Politècnica de Catalunya. EGEO - Enginyeria Geomàtica, Universitat Politècnica de Catalunya. EnGeoModels - Monitoring and Modelling in Engineering Geology, Prades Valls, Albert, Corominas Dulcet, Jordi, Lantada, Nieves, Matas Casado, Gerard, and Núñez Andrés, María Amparo
- Abstract
This paper presents a procedure for tracking rockfall trajectories and extracting kinematic parameters from both the impacts and the resultant fragments. A set of full scale rockfall experiments was performed in a quarry located in Vallirana, Barcelona (Spain). The study site was chosen due to the presence of a rigid discontinuity surface, inclined at 42° in the middle of the slope, whose configuration was expected to favor the breakage of the blocks. The trajectories of the blocks released and of the resultant fragments were recorded with three video cameras. A C++ program was specifically developed to track the 3D trajectory of blocks and fragments, and measure velocities before and after the impact. Two different modules were implemented, one for the blocks that break and one for those that do not. The trajectory of a non-fragmented block is obtained by comparing it to its 3D model. In this way, both the center of mass position and the orientation of the block are tracked. For fragmented blocks, the local coordinates of the fragments determined from the images are converted to terrain coordinates using the program we developed. A total of 16 blocks and 36 rock fragments after impact were tracked. The parameters obtained were georeferenced and linked to a common system of 3D terrestrial coordinates. The captured parameters allow obtaining the velocity distribution of fragments, the coefficient of restitution, and energy balance for the blocks that break. To our knowledge, this is the first attempt to capture kinematic parameters of rock fragments that result from the impact and breakage of rock blocks in full-scale tests. Although the analysis of the rockfall fragmentation phenomenon is beyond of this work, we have compared the performance of the fragmented and unbroken blocks. To this purpose, we have built 3D models of the rock fragments generated using images captured with a drone. The results indicate that blocks that fragment show higher rebound velocities an, Peer Reviewed, Postprint (published version)
- Published
- 2022
45. Comparative analysis of a new assessment of the seismic risk of residential buildings of two districts of Barcelona
- Author
-
Universitat Politècnica de Catalunya. Departament d'Enginyeria Civil i Ambiental, Barcelona Supercomputing Center, Universitat Politècnica de Catalunya. EGEO - Enginyeria Geomàtica, Aguilar Meléndez, Armando, Pujades Beneit, Lluís, Barbat Barbat, Horia Alejandro, Monterrubio Velasco, Marisol, Puente Álvarez, Josep de la, Lantada, Nieves, Universitat Politècnica de Catalunya. Departament d'Enginyeria Civil i Ambiental, Barcelona Supercomputing Center, Universitat Politècnica de Catalunya. EGEO - Enginyeria Geomàtica, Aguilar Meléndez, Armando, Pujades Beneit, Lluís, Barbat Barbat, Horia Alejandro, Monterrubio Velasco, Marisol, Puente Álvarez, Josep de la, and Lantada, Nieves
- Abstract
There are personal and institutional decisions that can increase the seismic resilience of the buildings in a city. However, some of these decisions are possible if we have basic knowledge of buildings’ seismic risk. The present document describes the main results of a detailed study of seismic vulnerability and seismic risk of residential buildings of Ciutat Vella (the ancient district of Barcelona) and Nou Barris (one of the newest districts of Barcelona). In this study, we assessed seismic risk according to the Vulnerability Index Method-Probabilistic named as VIM_P. Moreover, we analyzed the influence of basic buildings’ features in the final vulnerability and seismic risk values. For instance, we assessed the seismic vulnerability and the seismic risk of groups of buildings defined according to the number of stories of the buildings. Findings of this research reveal that the annual frequency of exceedance of the collapse damage state in Ciutat Vella buildings is, on average, 4.7 times higher than for the buildings in Nou Barris. Moreover, according to the Best vulnerability curve, 70.31% and 2.81% of Ciutat Vella and Nou Barris buildings, respectively, have an annual frequency of exceedance of the collapse damage state greater than 1 × 10–5., The present research has received partial funding from the European Union’s Horizon 2020 research 826 and innovation program (grant agreement Nº 823844, ChEESE CoE Project)., Peer Reviewed, Postprint (author's final draft)
- Published
- 2022
46. Análisis de susceptibilidad de deslizamientos superficiales a escala regional: efecto de futuros cambios en el Val d’Aran (Pirineo Central)
- Author
-
Universitat Politècnica de Catalunya. Departament d'Enginyeria Civil i Ambiental, Universitat Politècnica de Catalunya. Departament de Màquines i Motors Tèrmics, Universitat Politècnica de Catalunya. Doctorat en Enginyeria del Terreny, Universitat Politècnica de Catalunya. EnGeoModels - Monitoring and Modelling in Engineering Geology, Universitat Politècnica de Catalunya. CREMIT - Centre de Recerca de Motors i Instal·lacions Tèrmiques, Universitat Politècnica de Catalunya. EGEO - Enginyeria Geomàtica, Hurlimann Ziegler, Marcel, Medina Iglesias, Vicente César de, Puig i Polo, Càrol, Guo, Zizheng, Torra i Truncal, Ona, Gonzalez Díaz, Marta, Pinyol Guamis, Jordi, Universitat Politècnica de Catalunya. Departament d'Enginyeria Civil i Ambiental, Universitat Politècnica de Catalunya. Departament de Màquines i Motors Tèrmics, Universitat Politècnica de Catalunya. Doctorat en Enginyeria del Terreny, Universitat Politècnica de Catalunya. EnGeoModels - Monitoring and Modelling in Engineering Geology, Universitat Politècnica de Catalunya. CREMIT - Centre de Recerca de Motors i Instal·lacions Tèrmiques, Universitat Politècnica de Catalunya. EGEO - Enginyeria Geomàtica, Hurlimann Ziegler, Marcel, Medina Iglesias, Vicente César de, Puig i Polo, Càrol, Guo, Zizheng, Torra i Truncal, Ona, Gonzalez Díaz, Marta, and Pinyol Guamis, Jordi
- Abstract
Los deslizamientos superficiales desencadenados por precipitaciones intensas pueden causar daños importantes en diferentes tipos de infraestructuras e incluso provocar pérdidas de vidas humanas. La ocurrencia de estos deslizamientos está directamente relacionada con futuros cambios (climáticos y de usos de suelo). Por ello es necesario disponer de herramientas para planificar el territorio y de esta manera contribuir a la reducción del riesgo asociado a estos procesos. En este estudio, se presenta un nuevo modelo de susceptibilidad llamado FSLAM basado en la teoría del talud infinito. El modelo calcula las presiones de agua en el suelo mediante dos modelos hidrológicos que incorporan la lluvia antecedente y la lluvia desencadenante. FSLAM es un modelo de código abierto que se ha implementado en un plugin de QGIS para su uso. El modelo FSLAM se ha aplicado y validado en cuatro áreas de centenares de kilómetros cuadrados del Pirineo (Andorra y Val d’Aran), del Pre-Pirineo (Berguedà) y de la Cordillera Prelitoral Catalana (Montseny). Se ha evaluado su eficiencia mediante el análisis ROC (Receiver Operating Characteristic) mostrando unos valores de precisión (accuracy) altos y satisfactorios a pesar de las incertidumbres de muchos parámetros de suelo. Mediante FSLAM se ha analizado la influencia de los efectos del cambio climático y de futuros cambios en los usos y cubiertas del suelo en la susceptibilidad a generar deslizamientos en la zona de la Val d’Aran. Los resultados indican que los cambios en las cubiertas del suelo, especialmente la transformación de prados y arbustos a bosques, aumenta la estabilidad global en la zona de estudio. Por el contrario, el aumento de precipitación diaria para un periodo de retorno de 100 años provoca una reducción de la estabilidad. Sin embargo, el efecto del cambio de las cubiertas del suelo es más importante que el cambio en las condiciones pluviométricas y, por ello, la estabilidad global en esta zona de estudio aumentará en el f, El presente estudio ha sido financiado por dos proyectos nacionales: SMuCPhy (BIA 2015-67500-R) y EROSLOP (PID2019-104266RB-I00/AEI/10.13039/501100011033)., Postprint (published version)
- Published
- 2022
47. Comunicación de la geoinformación 3D mediante visores web y entornos inmersivos de realidad mixta en problemas de taludes y laderas
- Author
-
Universitat Politècnica de Catalunya. Departament d'Enginyeria Civil i Ambiental, Universitat Politècnica de Catalunya. EGEO - Enginyeria Geomàtica, Buill Pozuelo, Felipe, Pedraza Royo, Oriol, Janeras, Marc, Gili Ripoll, José Antonio, Guinau, Marta, Roca Barberi, Joan Ramon, Ferré i Oltra, Anna, Struth, Lucía, Universitat Politècnica de Catalunya. Departament d'Enginyeria Civil i Ambiental, Universitat Politècnica de Catalunya. EGEO - Enginyeria Geomàtica, Buill Pozuelo, Felipe, Pedraza Royo, Oriol, Janeras, Marc, Gili Ripoll, José Antonio, Guinau, Marta, Roca Barberi, Joan Ramon, Ferré i Oltra, Anna, and Struth, Lucía
- Abstract
La revolución experimentada por el uso creciente de la geoinformación 3D en la ingeniería geológica, gracias a los avances tecnológicos, que progresivamente han facilitado una disponibilidad de técnicas de adquisición de datos y de herramientas para su análisis. Junto a los avances experimentados en la disponibilidad de recursos de computación y almacenamiento en la nube, han impulsado la expansión de numerosas aplicaciones que permiten la difusión de la geoinformación 3D en la web. A pesar de estos avances científico-técnicos, es común ver los datos 3D simplificados en imágenes estáticas 2D, perdiendo parte su potencialidad comunicativa. El objetivo de esta comunicación es presentar el diseño y las funcionalidades de unos visores web 3D de código abierto como una herramienta de sencilla utilización con la que interactuar y visualizar los resultados. Así mismo, estamos ensayando las posibilidades de la realidad mixta como una experiencia plenamente inmersiva para lograr una mejor comunicación de la geoinformación 3D., Peer Reviewed, Postprint (published version)
- Published
- 2022
48. Simulación de desprendimientos rocosos con fragmentación mediante RockGIS
- Author
-
Universitat Politècnica de Catalunya. Departament d'Enginyeria Civil i Ambiental, Universitat Politècnica de Catalunya. Centre Específic de Recerca de Mètodes Numèrics en Ciències Aplicades i Enginyeria, Universitat Politècnica de Catalunya. EGEO - Enginyeria Geomàtica, Universitat Politècnica de Catalunya. EnGeoModels - Monitoring and Modelling in Engineering Geology, Matas Casado, Gerard, Lantada, Nieves, Corominas Dulcet, Jordi, Universitat Politècnica de Catalunya. Departament d'Enginyeria Civil i Ambiental, Universitat Politècnica de Catalunya. Centre Específic de Recerca de Mètodes Numèrics en Ciències Aplicades i Enginyeria, Universitat Politècnica de Catalunya. EGEO - Enginyeria Geomàtica, Universitat Politècnica de Catalunya. EnGeoModels - Monitoring and Modelling in Engineering Geology, Matas Casado, Gerard, Lantada, Nieves, and Corominas Dulcet, Jordi
- Abstract
La fragmentación en desprendimientos rocosos es un fenómeno complejo y poco comprendido que afecta a la evaluación del peligro y del riesgo. Sólo algunos modelos de simulación de caídas de rocas lo consideran explícitamente. RockGIS es un programa de simulación numérica de desprendimientos rocosos que considera la fragmentación, empleando una aproximación puntual de la masa y un modelo de rebote mediante coeficientes de restitución. Su principal innovación es la implementación del modelo de fragmentación fractal (Rockfall Fractal Fragmentation Model, RFFM) para distribuir la masa al romper los bloques. Los parámetros del modelo de fragmentación se calculan según las condiciones cinemáticas de cada impacto para reproducir diferentes escenarios de fragmentación. El funcionamiento de RockGIS ha sido verificado y validado mediante ensayos a escala real y en diversos desprendimientos rocosos naturales. En esta contribución presentamos la evolución de RockGIS en los últimos años y su aplicación a diversos casos de estudio., Este estudio ha sido desarrollado en el marco del Proyecto de Investigación “Caracterización y modelado de desprendimientos de rocas” con el acrónimo RockModels, financiado por el Ministerio de Economía y Competitividad de España, y cofinanciado por la Agencia Estatal de Investigación (AEI) y el Fondo Europeo de Desarrollo Regional (FEDER) sobre el marco del Plan Estatal de Investigación Científico-Técnica e Innovación con código de referencia BIA2016-75668-P (AEI/FEDER,UE) y el proyecto de investigación “Avances en el análisis cuantitativo del riesgo de caída de rocas (QRA) incorporando desarrollos en geomática (GeoRisk)” con referencia PID2019-103974RB-I00, financiado por MCIN/AEI/10.13039/501100 011033, Ministerio de Ciencia e Innovación (MCIN) y la Agencia Estatal de Investigación (AEI)., Postprint (published version)
- Published
- 2022
49. Medida de parámetros cinemáticos de bloques rocosos en un ensayo a escala real
- Author
-
Universitat Politècnica de Catalunya. Doctorat en Enginyeria del Terreny, Universitat Politècnica de Catalunya. Centre Específic de Recerca de Mètodes Numèrics en Ciències Aplicades i Enginyeria, Universitat Politècnica de Catalunya. Departament d'Enginyeria Civil i Ambiental, Universitat Politècnica de Catalunya. EGEO - Enginyeria Geomàtica, Universitat Politècnica de Catalunya. EnGeoModels - Monitoring and Modelling in Engineering Geology, Prades Valls, Albert, Corominas Dulcet, Jordi, Lantada, Nieves, Matas Casado, Gerard, Núñez Andrés, María Amparo, Universitat Politècnica de Catalunya. Doctorat en Enginyeria del Terreny, Universitat Politècnica de Catalunya. Centre Específic de Recerca de Mètodes Numèrics en Ciències Aplicades i Enginyeria, Universitat Politècnica de Catalunya. Departament d'Enginyeria Civil i Ambiental, Universitat Politècnica de Catalunya. EGEO - Enginyeria Geomàtica, Universitat Politècnica de Catalunya. EnGeoModels - Monitoring and Modelling in Engineering Geology, Prades Valls, Albert, Corominas Dulcet, Jordi, Lantada, Nieves, Matas Casado, Gerard, and Núñez Andrés, María Amparo
- Abstract
La evaluación del riesgo y el diseño de medidas de protección frente a desprendimientos de rocas requieren la predicción de las posibles trayectorias de los bloques susceptibles de desprenderse, así como la velocidad y la energía de llegada a las zonas que se deban proteger. Considerar la fragmentación introduce desafíos adicionales al modelado, tales como la energía disipada durante la fragmentación y la distribución de la energía restante entre los nuevos fragmentos. Para aclarar algunos de estos puntos se realizó un experimento a escala real, en el que se observaron las trayectorias de 16 bloques y de los fragmentos generados tras el impacto, empleando tres cámaras de video de alta velocidad. Para determinar la posición espacial de los bloques, hemos desarrollado un programa que permite calcular las velocidades, los momentos lineales, las energías en el instante anterior y posterior al impacto y, finalmente, los coeficientes de restitución asociados al impacto, Peer Reviewed, Objectius de Desenvolupament Sostenible::13 - Acció per al Clima, Objectius de Desenvolupament Sostenible::13 - Acció per al Clima::13.1 - Enfortir la resiliència i la capacitat d’adaptació als riscos relacionats amb el clima i els desastres naturals a tots els països, Postprint (published version)
- Published
- 2022
50. Rockfalls: analysis of the block fragmentation through field experiments
- Author
-
Universitat Politècnica de Catalunya. Departament d'Enginyeria Civil i Ambiental, Universitat Politècnica de Catalunya. Doctorat en Enginyeria del Terreny, Universitat Politècnica de Catalunya. Centre Específic de Recerca de Mètodes Numèrics en Ciències Aplicades i Enginyeria, Universitat Politècnica de Catalunya. EGEO - Enginyeria Geomàtica, Universitat Politècnica de Catalunya. EnGeoModels - Monitoring and Modelling in Engineering Geology, Gili Ripoll, José Antonio, Ruiz Carulla, Roger, Matas Casado, Gerard, Moya Sánchez, José, Prades Valls, Albert, Corominas Dulcet, Jordi, Lantada, Nieves, Núñez Andrés, María Amparo, Buill Pozuelo, Felipe, Puig i Polo, Càrol, Martínez Bofill, Joan, Salo Salgado, Lluis, Mavrouli, Olga Christina, Universitat Politècnica de Catalunya. Departament d'Enginyeria Civil i Ambiental, Universitat Politècnica de Catalunya. Doctorat en Enginyeria del Terreny, Universitat Politècnica de Catalunya. Centre Específic de Recerca de Mètodes Numèrics en Ciències Aplicades i Enginyeria, Universitat Politècnica de Catalunya. EGEO - Enginyeria Geomàtica, Universitat Politècnica de Catalunya. EnGeoModels - Monitoring and Modelling in Engineering Geology, Gili Ripoll, José Antonio, Ruiz Carulla, Roger, Matas Casado, Gerard, Moya Sánchez, José, Prades Valls, Albert, Corominas Dulcet, Jordi, Lantada, Nieves, Núñez Andrés, María Amparo, Buill Pozuelo, Felipe, Puig i Polo, Càrol, Martínez Bofill, Joan, Salo Salgado, Lluis, and Mavrouli, Olga Christina
- Abstract
Fragmentation is a common feature of rockfall that exerts a strong control on the trajectories of the generated blocks, the impact energies, and the runout. In this paper, we present a set of four real-scale rockfall tests aimed at studying the fragmentation of the rocky blocks, from the global design of the field procedure to the data analysis and the main results. A total of 124 limestone, dacite, or granite blocks ranging between 0.2 and 5 m3 were dropped from different heights (8.5 to 23.6 m) onto four slopes with different shapes (single or double bench) and slope angles (42º to 71º). The characteristics of the blocks, in particular the size, surface texture and joint condition, were measured before the drops. The trajectories of the blocks and both the initial and the impact velocities were tracked and recorded by means of three high-speed video cameras. A total of 200 block-to-ground impacts have been studied. On average, 40% of the blocks broke upon impact on the slope or on the ground, making it necessary to measure the fragments. The initial and final sizes of the blocks/fragments were measured by hand with tape, though photogrammetric techniques (UAV and terrestrial) were also used for comparison purposes. The information gathered during the field tests provides a deep insight into the fragmentation processes. On the one hand, the high-resolution slow-motion videos help to describe when and how the block breakage takes place and the spatial distribution of the pieces. On the other hand, it is possible to compute the block trajectories, the velocities, and the energy losses using videogrammetry. The results include, for instance, a block average fragmentation of 54% and 14% for the limestone and granitoids, respectively; the systematic inventory of the size fragments, which may be used for fitting the power law distributions; and after each breakage, the total angle of aperture occupied by the fragments has been measured, with values in the range 25º–145º., The authors acknowledge the support of the Spanish Ministry of Economy and Competitiveness for the research projects RockRisk (BIA2013-42582-P), RockModels (BIA2016-75668-P, AEI, ERDF/FEDER, UE) and GeoRisk (PID2019-103974RB-I00/AEI/10.13039/501100011033). GeoRisk is funded by the Agencia Estatal de Investigación (AEI) on the framework of the Plan for Scientific-Technical Research and Innovation. The support of the Spanish Ministry of Education (grants to the second and third authors, codes FPU13/04252 and BES-2014-069795, respectively) and the BBVA Foundation (thirteenth author’s contract) is also appreciated. The collaboration of Canteras Hermanos Foj and Canteras Ponderosa S.A., Marc Janeras, and S. Moreno is greatly acknowledged. Finally, we thank two anonymous reviewers and the Editor who helped to improve the structure and content of the final version. Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature., Peer Reviewed, Postprint (published version)
- Published
- 2022
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.